Status:

UNKNOWN

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Lead Sponsor:

Beijing Continent Pharmaceutical Co, Ltd.

Collaborating Sponsors:

Shanghai Genomics, Inc.

GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Conditions:

Radiation Pneumonitis

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.

Eligibility Criteria

Inclusion

  • 18-70 years old (include 18 and 70 years), male or female
  • The pathological diagnosis of lung cancer, with non-small cell lung cancer (NSCLC) staging IIIA or IIIB, and small cell lung cancer (SCLC) in council deadline
  • General condition assessment, ECOG score of 0-1
  • Enough heart, liver and kidney function, such as AST, ALT, LDH≤2 times ULN such as plasma total bilirubin, creatinine ≤1.5 times ULN; hematopoietic function enough, such as neutrophils ≥4.0 x109 / L, platelets ≥100 x109 / L
  • The expected survival at 6 months or more
  • Subject is able to eat solid food
  • The initial radical thoracic radiotherapy treatment
  • The clinical diagnosis of radiation-induced lung injury in Grade 2 or above
  • The duration of radiation-induced lung injury in less than 1 month
  • Signed informed consent

Exclusion

  • Radiation-induced lung injury has entered the chronic phase
  • A history of chronic bronchitis, emphysema, or a history of cor pulmonale
  • Lung resection surgery
  • Cancer progression
  • Pulmonary infection
  • Associated with other serious diseases: such as occurred within 6 months of myocardial infarction, uncontrolled diabetes etc.
  • With active peptic ulcer
  • Pregnant women and patients with mental disease
  • Those who participate in clinical trials of other drugs within 3 months
  • Investigator judge does not apply to participate in the trial

Key Trial Info

Start Date :

January 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT02296281

Start Date

January 1 2015

Last Update

November 20 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.